Public Sector Pension Investment Board lifted its position in Glaukos Corporation (NYSE:GKOS - Free Report) by 50.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 303,984 shares of the medical instruments supplier's stock after buying an additional 102,241 shares during the period. Public Sector Pension Investment Board owned approximately 0.51% of Glaukos worth $50,926,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of GKOS. BlackRock Inc. acquired a new stake in shares of Glaukos in the 2nd quarter worth $1,333,318,000. Janus Henderson Group PLC increased its holdings in shares of Glaukos by 77.2% during the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier's stock valued at $575,844,000 after acquiring an additional 2,329,608 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Glaukos during the second quarter valued at about $679,614,000. Primecap Management Co. CA purchased a new position in shares of Glaukos in the 2nd quarter valued at approximately $424,969,000. Finally, William Blair Investment Management LLC acquired a new stake in Glaukos in the 2nd quarter worth approximately $92,476,000. Institutional investors own 99.04% of the company's stock.
Insider Activity
In other news, Director Gilbert H. Kliman sold 2,500 shares of the company's stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total value of $632,500.00. Following the transaction, the director owned 37,406 shares of the company's stock, valued at $9,463,718. This represents a 6.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Joseph Gilliam sold 861 shares of the stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $250.00, for a total transaction of $215,250.00. Following the transaction, the chief operating officer directly owned 71,602 shares of the company's stock, valued at approximately $17,900,500. This trade represents a 1.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 48,278 shares of company stock valued at $11,911,705. 5.90% of the stock is owned by company insiders.
Glaukos Trading Down 4.4%
Shares of Glaukos stock opened at $232.59 on Thursday. The stock has a market cap of $13.77 billion, a P/E ratio of -79.11 and a beta of 0.68. The stock's 50 day simple moving average is $188.17 and its 200-day simple moving average is $148.89. Glaukos Corporation has a 1-year low of $91.83 and a 1-year high of $255.18. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09.
Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The business had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. During the same period in the prior year, the business earned ($0.16) earnings per share. The business's revenue was up 58.0% compared to the same quarter last year. Analysts predict that Glaukos Corporation will post 0.50 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on GKOS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Glaukos in a report on Thursday, October 15th. Wells Fargo & Company lifted their price target on Glaukos from $178.00 to $226.00 and gave the stock an "overweight" rating in a research report on Thursday, October 29th. Needham & Company LLC boosted their price target on Glaukos from $201.00 to $251.00 and gave the company a "buy" rating in a research note on Thursday, October 29th. Stifel Nicolaus raised their target price on shares of Glaukos from $190.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. Finally, Zacks Research raised Glaukos from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Glaukos presently has an average rating of "Moderate Buy" and an average price target of $218.00.
Get Our Latest Report on GKOS
Glaukos Profile
(
Free Report)
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Recommended Stories
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.